hero image
Peter Gulick, DO FACP, FIDSA, FACOI - Michigan State University. East Lansing, MI, US

Peter Gulick, DO FACP, FIDSA, FACOI Peter Gulick, DO FACP, FIDSA, FACOI

Professor of Medicine | Michigan State University

East Lansing, MI, UNITED STATES

Take care of HIV/AIDS patients as well as Hepatitis C, B patients at 3 sites in Michigan

Media

Publications:

Documents:

Photos:

loading image

Videos:

Audio:

Biography

Peter Gulick is currently an associate professor of medicine at Michigan State University, College of Osteopathic Medicine, and serves as adjunct faculty in the College of Human Medicine and the College of Nursing.

He received training in two primary specialties: infectious diseases at the Cleveland Clinic Foundation and medical oncology at Roswell Park Memorial Institute.

Gulick is director of the MSU HIV/Hepatitis clinic where his primary area of interest is HIV therapy, as well as hepatitis B, hepatitis C and co-infection therapy.

In addition to teaching, Gulick has cared for HIV patients for 20 years and hepatitis C patients for 10 years.

He has served on the Lung Cancer Advisory Committee through the State of Michigan's Department of Community Health , as well as the HIV/AIDS Prevention and Intervention Section, the Michigan Cancer Consortium and the Region 1 Smallpox Planning Team.

Industry Expertise (3)

Writing and Editing Research Education/Learning

Areas of Expertise (3)

Hepatitis C Hiv/Aids Hepatitis B

Education (7)

Cleveland Clinic Foundation: Infectious Diseases 1983

Roswell Park Memorial Institute: Medical Oncology 1981

Cleveland Clinic Foundation: Internal Medicine 1980

Detroit Osteopathic Hospital: Internship 1977

Midwestern University: D.O. 1976

Michigan State University: M.D.

University of Michigan,: M.A., Health Managements and Policy

Research Focus (1)

Translational HIV Research

I have a MSU Registry of over 500 HIV patients with protected data for HIV research. There are currently 2 HIH grants for HIV research. We also do Pharmaceutical sponsored Drug trials on New HIV medication.

Contact